Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
PF-06809247 · 1 trial · 1 indication
Binding of \[11C\]PF-06809247 will be assessed by the evaluation of net uptake rate constant Ki (mL/min/g) in the various brain regions modeled, as data permit.
| Arm | Type | Description |
|---|---|---|
| [11C]PF-06809247 | EXPERIMENTAL | A dose intravenous injection of \[11C\]PF-06809247 followed by PET scanning. |
| Name | Type | Description |
|---|---|---|
| [11C]PF-06809247 | DRUG | PET Tracer |
Inclusion Criteria: * Healthy male subjects who, at the time of screening, are between the ages of 18 and 55 years, inclusive. * Body Mass Index (BMI) of 17.5 to 30.5 kg/m2; and a total body weight \>50 kg (110 lbs). Exclusion Criteria: -Evidence or history of clinically significant hematological...
PF-06809247 is an investigational small molecule being studied for use in neuroinflammation. It is being developed by Pfizer, Inc. as a potential diagnostic or therapeutic agent for conditions involving neuroinflammation, though it is still in early clinical development.
PF-06809247 is a small molecule developed as a novel PET tracer, designed to bind to targets involved in neuroinflammation. As a PET tracer, it is intended to enable imaging of neuroinflammatory processes in the brain, though the specific molecular target has not been disclosed.
PF-06809247 is being developed by Pfizer, Inc., a multinational pharmaceutical company traded on the New York Stock Exchange under the ticker symbol PFE. The drug is currently in Phase 1 clinical development for neuroinflammation.
PF-06809247 is in Phase 1 clinical development. It is an investigational drug, not yet approved by regulatory authorities. A Phase 1 trial has been completed, and the drug remains under investigation for use in neuroinflammation.
PF-06809247 has one completed Phase 1 clinical trial, registered as NCT03100136. This study, titled 'Test Re-Test Reliability of [11C]PF-06809247 as a Novel PET Tacer,' enrolled 7 healthy male volunteers in the United States to assess the reliability of the PET tracer.
Yes, PF-06809247 is also known as [11C]PF-06809247. The [11C] designation indicates that the molecule is labeled with carbon-11, a radioactive isotope used in positron emission tomography (PET) imaging. The completed clinical trial used this radiolabeled form to study neuroinflammation.